Clinical Trials for Non-Small Cell Lung Cancer

PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates M9140, an antibody-drug conjugate targeting CEACAM5, in adult patients with advanced gastric cancer, non-small cell lung cancer, and pancreatic cancer who have progressed or been intolerant to conventional therapies, assessing its monotherapy and combination efficacy in a multicenter setting.

ClinicalTrials.gov ID: NCT06710132

LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adult patients with non-small cell and small cell lung cancers experiencing oligo-progression while on stable systemic therapy, assessing the addition of locally ablative therapies like stereotactic ablative radiotherapy (SABR) and interventional radiology ablation for up to five or fewer metastatic lesions.

ClinicalTrials.gov ID: NCT06103682

A Phase II Adaptive Study of Local Ablative Therapy (LAT) for Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Using Minimal Residual Disease (MRD) as an Integral Biomarker

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets Stage IV metastatic NSCLC patients with insufficient response to first-line systemic therapy and limited metastatic lesions, assessing the efficacy of Local Ablative Therapy (LAT), including radiation, surgery, or RF ablation, on reducing minimal residual disease levels and controlling cancer progression.

ClinicalTrials.gov ID: NCT05429320

SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adults with stage IVA/IVB or locally advanced NSCLC unsuitable for standard chemoradiation, using split-course adaptive radiation therapy combined with immunotherapy agents like pembrolizumab and ipilimumab, which enhance immune targeting of cancer cells, with or without standard chemotherapy like carboplatin.

ClinicalTrials.gov ID: NCT05501665

A Phase II Randomized Study of Safety and Efficacy of a Multiple Antigen Vaccine (STEMVAC) in Non-Small-Cell Lung Cancer Patients

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial targets adult patients with stage IV non-squamous or squamous non-small cell lung cancer who have undergone prior chemoimmunotherapy with pembrolizumab, focusing on evaluating the safety and efficacy of the STEMVAC vaccine, a DNA-based vaccine targeting multiple antigens to enhance T-cell mediated anti-tumor activity, in combination with the adjuvant sargramostim.

ClinicalTrials.gov ID: NCT05242965

A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: The trial investigates GDC-6036, a KRAS G12C inhibitor, as monotherapy and in combination with anticancer agents like atezolizumab, cetuximab, and bevacizumab, in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. Eligible patients should not have active brain metastases, significant cardiovascular dysfunction, or liver disease.

ClinicalTrials.gov ID: NCT04449874

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates AU-007, a monoclonal antibody that redirects IL-2 from regulatory T cells to effector T and NK cells, in patients with unresectable, locally advanced, or metastatic solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer, who have limited standard treatment options. Treatments involve AU-007 alone or in combination with low-dose aldesleukin and avelumab, aiming to enhance anti-tumor effects while minimizing IL-2-related toxicities.

ClinicalTrials.gov ID: NCT05267626

A Biomarker Study of Low-Dose IL-2 Plus Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves newly diagnosed stage IV non-small cell lung cancer (NSCLC) patients, with adenocarcinoma or squamous cell carcinoma, who have not received prior systemic therapy and whose tumors express PD-L1, evaluating the combination of pembrolizumab, an anti-PD-1 monoclonal antibody, with low-dose IL-2 to assess immune response and safety.

ClinicalTrials.gov ID: NCT05493566

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates the safety and efficacy of [68Ga]Ga DOTA-5G for imaging and [177Lu]Lu DOTA-ABM-5G for treatment, targeting the integrin αvβ6, in up to 40 patients with metastatic non-small cell lung cancer who have progressed after previous treatments.

ClinicalTrials.gov ID: NCT06228482

A Phase II Study of Amivantamab in Participants With MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP SUB-STUDY)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial involves patients with stage IV or recurrent non-small cell lung cancer with MET amplification, excluding those with known actionable oncogenic alterations and prior MET inhibitor treatment. Participants receive amivantamab-vmjw, a bispecific antibody targeting EGFR and MET receptors, administered intravenously.

ClinicalTrials.gov ID: NCT06116682